Drug intelligence / Profile preview

Lianxia Xiaopi

Development stage: Unknown
Lead developer: Tasly Pharmaceutical
Administration: Oral

Overview

Lianxia Xiaopi is a Traditional Chinese Medicine (TCM) capsule developed by Tianjin Tasly New Resource Pharmaceutical for the treatment of functional dyspepsia. It is specifically indicated for patients presenting with the 'Pi Man Han Re Cuo Zong' syndrome (Spleen Fullness with Cold-Heat Complex). The formulation has been evaluated in Phase II clinical trials in China (e.g., CTR20140016) to assess its efficacy and safety in improving symptoms such as epigastric distension, bloating, and early satiety compared to the prokinetic agent domperidone. As a botanical combination, it is designed to regulate gastrointestinal motility and alleviate dyspeptic symptoms through a multi-target approach characteristic of herbal medicine.

Other names: Lianxia Xiaopi Capsule连夏消痞胶囊

Beyond the preview

Go deeper on Lianxia Xiaopi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lianxia Xiaopi.

Explore the full profile